Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
about
Estrogen as therapy for breast cancer.Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerTreating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerAromatase inhibitors and inactivators in breast cancerCost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.Breast cancer (metastatic).Anti-aromatase agents in the treatment and prevention of breast cancer.Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancerAromatase inhibitors in breast cancer: an update.First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?Clinical utility of exemestane in the treatment of breast cancerHigh-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II studyRole of aromatase inhibitors in breast cancer.Sequencing of aromatase inhibitors.Understanding the mechanisms of aromatase inhibitor resistance.Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.Update on the use of aromatase inhibitors in breast cancer.Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trialEfficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitorsImpact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy VolunteersAromatase inhibition 2013: clinical state of the art and questions that remain to be solvedPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupPhase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancerAlopecia with endocrine therapies in patients with cancer.Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane.Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor.Additive endocrine therapy for advanced breast cancer - back to the future.Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expressionRole of fulvestrant in the management of postmenopausal breast cancer.Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Aromatase inhibitors and other novel agents in breast cancer treatment.High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
P2860
Q24802521-10E2991B-03B0-4311-8700-1910F64AB231Q26764987-C4B4A972-4A66-46FC-ADF4-049C00100733Q26785496-2019305A-9EE9-4F70-B2B7-E8D589ACAF00Q26825584-4B4494A3-9ABB-4264-9B47-58298EC0C1F1Q28362331-D795256F-F14E-4C47-9CB9-350597FC78F7Q31911601-3FD72C31-6D9A-4A84-BA9F-AC96B6243C64Q33448016-BCD20589-1F20-444E-AD7A-A60B0FEC0377Q34608612-1D5D2F40-3F09-4116-B49E-89B70082882EQ34725685-1B9EB126-015E-48A9-94B9-82FD0D5C92FDQ35039491-2541C389-B8E9-454A-A538-EEAA225F9D1AQ35622444-3E8A2834-9468-4E9B-86E9-C8641B3616FEQ35683807-7F1CC284-595D-44C0-8470-89C72E914887Q35995140-C222C5CF-32F6-43E6-863F-35F82EF17FC6Q36229436-18370097-B627-4934-966C-1EA4A239DE74Q36229445-5F5A262D-1C57-4112-A6E3-85D2BFBC449BQ36393053-55916A18-69D7-4A16-9EEF-04FF5648B50BQ36415607-0E8E8B61-3ED4-413A-8E4C-281D5913365AQ36613881-BA843D8B-05A1-4E42-8DDF-9B9390C52BDEQ36616775-932FABDA-8351-43AE-AF7B-EAD37CB6A02BQ36684234-FEFEA95E-D0E3-492B-9187-BAC764327D52Q36729512-784A585A-F8C0-45F9-823C-214425956BE0Q36764008-58D4354B-569F-40A2-B5BA-F1BBBC4FD8DAQ36940755-E76449A2-32A0-4397-A5C8-C98A53D4AE1FQ36946008-A080B184-C481-4143-820B-F96A0562C736Q37119390-530424E0-150E-449F-A2F4-4193CFD66A4EQ37214089-9E928DFE-6F25-4A5C-9052-FF2FED167BB5Q37247197-C73AB344-9DC1-4C49-8121-41FA0ABDC91CQ37355561-1B0CB17A-3078-4C2A-B277-8BED9D9A557EQ37355574-A4EC4F76-47C9-4D16-9895-FBDF15877A8BQ37366511-5C442B91-1756-49E9-BE86-78DD9756BD07Q37607281-0366EC3F-7A3B-4A11-878D-AA74211EE05FQ37622884-7DA183D9-75B0-4E17-A22D-61F281940B49Q37707677-0B6F1265-5D45-45FB-B4AE-4A7DD104C1DFQ37952234-E52EA776-413B-45E6-88DB-470F0654ACB3Q38044021-ED5D8045-E677-4D9A-BADE-CE3AF7FDD230Q38880515-E2C08D14-C4F9-4B00-940F-27E5B26BCA94Q39185424-27AD6CBC-18C6-4385-97EC-64BFEBF800B1Q40409345-FE12283B-3E52-4758-8FAF-E030924DBB54Q43717824-150CF578-3B14-4BB9-BA62-B85F3B557DBCQ44107109-D0578D66-4193-440D-A6B1-E9D8185FC42E
P2860
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@ast
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@en
type
label
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@ast
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@en
prefLabel
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@ast
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@en
P2093
P1476
Activity of exemestane in meta ...... inhibitors: a phase II trial.
@en
P2093
A Arkhipov
E Mickiewicz
E di Salle
G Massimini
M Tubiana-Hulin
P304
P356
10.1200/JCO.2000.18.11.2234
P407
P577
2000-06-01T00:00:00Z